Treatment with semaglutide leads to clinically significant decreases in haemoglobin A1C (HbA1c) and body weight in patients with type 2 diabetes (T2D) across the SUSTAIN 1–7 trials, regardless of race and ethnicity, results of a posthoc analysis have shown.
Levels of C-reactive protein (CRP) appear to correlate with the insulin requirements of type 2 diabetes mellitus (T2DM) patients admitted for lumbar spinal canal stenosis surgery in the acute postoperative phase, a new study has found.
Evidence concerning the causal effect of age at menarche (AAM) on the risk of cardiometabolic diseases in adult life is lacking, a recent study has shown. The associations seen in epidemiological studies between AAM and cardiometabolic traits appear to be largely facilitated through excessive adiposity.
Overall morbidity and mortality are greater in women with Turner Syndrome (TS), but use of hormone replacement therapy (HRT) may confer benefits to those with 45,X karyotype, particularly on stroke, hypertension and endocrine conditions, suggests a study. However, HRT shows no clear effect on mortality.
The GLP-1 receptor agonist* dulaglutide may reduce the incidence of stroke, particularly ischaemic stroke, in individuals with type 2 diabetes (T2D) and cardiovascular (CV) risk factors, according to findings of an exploratory analysis of the REWIND** trial.
New drug applications approved by US FDA as of 16 - 31 January 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The use of cabergoline as bridge treatment in Cushing’s disease patients who have undergone radiotherapy does not appear to affect initial remission but is associated with increased recurrence following initial remission, a study reports.
Individuals with type 2 diabetes (T2D) who are prescribed an SGLT2* inhibitor may have a reduced risk for developing gout compared with those who are prescribed a GLP-1** receptor agonist, according to a study from the US.
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.